Learning disability affects 3% of the population. Severe types of learning disability are more likely to have an underlying genetic cause but diagnosis is difficult because many different genetic abnormalities may be involved. Obtaining a diagnosis is important so that patients can be managed appropriately and their families can be given accurate information. We aim to use new types of genetic testing which will make it possible to screen for several different genetic abnormalities which cause learning disability at the same time, so improving the accuracy and speed of diagnosis in the group of patients with severe learning disability. We will focus particularly on patients where seizures and behavioural problems are also present.This will enable more patients to be diagnosed accurately, reduce the number of hospital appointments needed and ultimately be more cost- effective.
Study Type
OBSERVATIONAL
Enrollment
119
Central Manchester University Hospitals NHS Foundation Trust
Manchester, United Kingdom
Genetic abnormality identified by microarray or Next Generation Sequencing
Abnormalities identified upon results of testing, the normal timeframe for this is up to 6 months after collecting blood sample.
Time frame: up to 6 months following consent
Cost effectiveness vs normal care
This analysis will be performed for all participants following close of recruitment \& follow up, and will be completed by the time the study ends.
Time frame: By the end of the study (December 2014)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.